-
Product Insights
Tyrosine Protein Kinase BTK – Drugs In Development, 2023
Global Markets Direct’s Tyrosine Protein Kinase BTK provides in depth analysis on Tyrosine Protein Kinase BTK targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase...
-
Product Insights
PTA Peripheral DCB Catheters Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
PTA Peripheral DCB Catheters Pipeline Market Report Overview A PTA Peripheral DCB Catheter is a drug-coated percutaneous transluminal angioplasty (PTA) balloon intended to prevent restenosis or restenosis of the peripheral arteries. PTA Peripheral DCB catheters provide fast, short-term, homogenous, local drug delivery to the vessel wall while preserving the anatomy of the vessel, promoting enhanced vessel healing, and reducing the need for prolonged dual antiplatelet therapy. They can be used to treat native and in-stent restenosis (ISR), bifurcations, small vessels,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pirtobrutinib in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pirtobrutinib in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pirtobrutinib in Diffuse Large B-Cell Lymphoma Drug Details: Pirtobrutinib (Jaypirca)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pirtobrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pirtobrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pirtobrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pirtobrutinib in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pirtobrutinib in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pirtobrutinib in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pirtobrutinib in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pirtobrutinib in Marginal Zone B-cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pirtobrutinib in Marginal Zone B-cell Lymphoma Drug Details: Pirtobrutinib (Jaypirca)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pirtobrutinib in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pirtobrutinib in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pirtobrutinib in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: Pirtobrutinib (Jaypirca)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pirtobrutinib in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pirtobrutinib in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pirtobrutinib in Follicular Lymphoma Drug Details: Pirtobrutinib (Jaypirca) is an anti-neoplastic agent. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TT-01488 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TT-01488 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TT-01488 in Follicular Lymphoma Drug Details: TT-01488 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TT-01488 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TT-01488 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TT-01488 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: TT-01488...